Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines

International Journal of Cancer

Volumn 139, Issue 3, 2016, Pages 510-517

  Brotherton, Julia M L ^a,b   Jit, Mark ^c,d   Gravitt, Patti E ^e   Brisson, Marc ^f   Kreimer, Aimée R ^g   Pai, Sara I ^h   Fakhry, Carole ⁱ   Monsonego, Joseph ^j   Franceschi, Silvia ^k  

^a National HPV Vaccination Program Register   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^f UNIVERSITÉ LAVAL   (Canada)

^g NATIONAL CANCER INSTITUTE   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j Institut du Col   (France)

^k INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

more..

Author keywords

cervical cancer; HPV; oropharyngeal cancer; vaccine

Indexed keywords

WART VIRUS VACCINE;

ACTIVE IMMUNIZATION; CANCER RISK; CANCER SCREENING; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; HEAD AND NECK CANCER; HUMAN; INFECTION PREVENTION; INJECTION SITE REACTION; MEDICAL PRACTICE; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; RESEARCH PRIORITY; REVIEW; UTERINE CERVIX CANCER; CLASSIFICATION; EUROPE; FEMALE; HEAD AND NECK NEOPLASMS; IMMUNOLOGY; INCIDENCE; MALE; MASS SCREENING; NEOPLASMS; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EUROPE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INCIDENCE; MALE; MASS SCREENING; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84967189749     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30063     Document Type: Review

References (114)

1. Roteli-Martins CM, Naud P, De Borba P, et al., Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother 2012; 8: 390-97.
2. Ferris D, Samakoses R, Block SL, et al., Long-term study of a quadrivalent human papillomavirus vaccine. Pediatrics 2014; 134: e657-65.
3. Schwarz TF, Huang LM, Lin TY, et al., Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial. Pediatr Infect Dis J Dec 2014; 33: 1255-61.
4. Schiller JT, Castellsague X, Garland SM., A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30 (Suppl 5): F123-38.
5. Wheeler CM, Castellsagué X, Garland SM, et al., Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13: 100-10.
6. Einstein MH, Takacs P, Chatterjee A, et al., Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial. Hum Vaccin Immunother 2014; 10: 3435-45.
7. Brown D, Muller M, Sehr P, et al., Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18. Vaccine 2014; 32: 5880-87.
8. Palefsky JM, Giuliano AR, Goldstone S, et al., HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365: 1576-85.
9. Giuliano AR, Palefsky JM, Goldstone S, et al., Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011; 364: 401-11.
10. Klooster TMS, de Ridder, MA, Kemmeren JM, et al., Examining a possible association between human papilloma virus (HPV) vaccination and migraine: results of a cohort study in the Netherlands. Eur J Pediatr 2015; 174: 641-649.
11. Moro PL, Zheteyeva Y, Lewis P, et al., Safety of quadrivalent human papillomavirus vaccine (Gardasil) in pregnancy: adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006-2013. Vaccine 2015; 33: 519-22.
12. Scheller NM, Svanstrom H, Pasternak B, et al., Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA 2015; 313: 54-61.
13. Goss MA, Lievano F, Seminack MM, et al., No adverse signals observed after exposure to human papillomavirus type 6/11/16/18 vaccine during pregnancy: 6-year pregnancy registry data. Obstet Gynecol 2014; 123 (Suppl 1): 93S
14. Angelo MG, David MP, Zima J, et al., Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiol Drug Saf 2014; 23: 466-79.
15. Grimaldi-Bensouda L, Guillemot D, Godeau B, et al., Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med 2014; 275: 398-408.
16. Stokley S, Jeyarajah J, Yankey D, et al., Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014-United States. MMWR Morb Mortal Wkly Rep 2014; 63: 620-624.
17. Vichnin M, Bonanni P, Klein NP, et al., An overview of quadrivalent human papillomavirus vaccine safety-2006 to 2015. Pediatr Infect Dis J 2015; Sep; 34: 983-91.
18. ANSM/CNAMTS. Vaccins anti-HPV et risque de maladies auto-immunes: étude pharmacoépidémiologique. Rapport final, Septembre 2015. Available at: http://ansm.sante.fr/S-informer/Actualite/Vaccination-contre-les-infections-a-HPV-et-risque-de-maladies-auto-immunes-une-etude-Cnamts-ANSM-rassurante-Point-d-information
19. Global Advisory Committee on Vaccine Safety Statement on the continued safety of HPV vaccination. March 12, 2014 Available at: http://www.who.int/vaccine-safety/committee/topics/hpv/GACVS-Statement-HPV-12-Mar-2014.pdf?ua=1, accessed on March 26, 2015.
20. Drolet M, Benard E, Boily MC, et al., Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015; 15: 565-80.
21. Elfstrom KM, Lazzarato F, Franceschi S, et al., Human papillomavirus vaccination of boys and extended catch-up vaccination: effects on the resilience of programs. J Infect Dis 2016; 213: 199-205.
22. World Health Organization. Meeting of the strategic advisory group of experts on immunization, April 2014-conclusions and recommendations. Wkly Epidemiol Rec 2014; 89: 221-36.
23. Dobson SR, McNeil S, Dionne M, et al., Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013; 309: 1793-802.
24. Romanowski B, Schwarz TF, Ferguson LM, et al., Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: Results from a randomized study. Hum Vaccin Immunother 2014; 10: 1155-65.
25. Stanley MA, Sudenga SL, Giuliano AR., Alternative dosage schedules with HPV virus-like particle vaccines. Expert Rev Vaccines 2014; 13: 1027-38.
26. Jit M, Brisson M, Laprise JF, Choi YH., Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model. BMJ 2015; 350: g7584
27. Romanowski B, Schwarz TF, Ferguson L, et al., Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: five-year clinical data and modelling predictions from a randomized study. Hum Vaccin Immunother 2016; 12: 20-29.
28. Kreimer AR, Struyf F, Del Rosario-Raymundo MR, et al., Efficacy of fewer than three doses of an HPV-16/18 AS04 adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine Trial and the PATRICIA Trial. Lancet Oncol 2015; 16: 775-86.
29. Kreimer AR, Rodriguez AC, Hildesheim A, et al., Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011; 103: 1444-1451.
30. Sankaranarayanan R, Prabhu PR, Pawlita M, et al., Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicenter prospective cohort study. Lancet Oncol 2016; 17: 67-77.
31. Giacomet V, Penagini F, Trabattoni D, et al., Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults. Vaccine 2014; 32: 5657-61.
32. Kahn JA, Xu J, Kapogiannis BG, et al., Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis 2013; 57: 735-744.
33. Denny L, Hendricks B, Gordon C, et al., Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Vaccine 2013; 31: 5745-5753.
34. Kojic EM, Kang M, Cespedes MS, et al., Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis 2014; 59: 127-135.
35. Toft L, Storgaard M, Muller M, et al., Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. J Infect Dis 2014; 209: 1165-1173.
36. Toft L, Tolstrup M, Storgaard M, et al., Vaccination against oncogenic human papillomavirus infection in HIV-infected populations: review of current status and future perspectives. Sex Health 2014; 11: 511-23.
37. Rainone V, Giacomet V, Penagini F, et al., Human papilloma virus vaccination induces strong human papilloma virus specific cell-mediated immune responses in HIV-infected adolescents and young adults. Aids 2015; 29: 739-43.
38. Joura EA, Giuliano AR, Iversen OE, et al., A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015; 372: 711-23.
39. Luxembourg A, Bautista O, Moeller E, et al., Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine. Contemp Clin Trials 2015; 42: 18-25.
40. Luxembourg A, Brown D, Bouchard C, et al., Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine. Hum Vaccin Immunother 2015; 11: 1313-22.
41. Drolet M, Laprise JF, Boily MC, et al., Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. Int J Cancer 2014; 134: 2264-2268.
42. Brisson M, Laprise J-F, Chesson HW, et al., Health and economic impact of switching from a 4-Valent to a 9-Valent HPV vaccination program in the United States. J Natl Cancer Inst 2016; 108:djv282.
43. Kiatpongsan S, Kim JJ., Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two East African countries. PLoS One 2014; 9: e106836
44. Parkin DM, Bray F., Chapter 2: The burden of HPV-related cancers. Vaccine 2006; 24(Suppl3): S3/11-25.
45. Guan P, Howell-Jones R, Li N, et al., Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012; 131: 2349-59.
46. Serrano B, Alemany L, Tous S, et al., Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 2012; 7: 38
47. Joura EA, Ault KA, Bosch FX, et al., Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol Biomarkers Prev 2014; 23: 1997-2008.
48. Lehtinen M, Paavonen J, Wheeler CM, et al., Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13: 89-99.
49. Malagon T, Drolet M, Boily MC, et al., Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12: 781-89.
50. Kjaer SK, Frederiksen K, Munk C, et al., Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010; 102: 1478-1488.
51. Jit M, Chapman R, Hughes O, et al., Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ 2011; 343: d5775
52. Van de Velde N, Boily MC, Drolet M, et al., Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst 2012; 104: 1712-23.
53. A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 years Old (V503-101). Available at: https://clinicaltrials.gov/ct2/show/NCT01984697, accessed on August 27, 2015.
54. Peto J, Gilham C, Fletcher O, et al., The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004; 364: 249-56.
55. Lynge E, Rygaard C, Baillet MV, et al., Cervical cancer screening at crossroads. APMIS 2014; 122: 667-73.
56. Dunne EF, Stokley S, Chen W, et al., Human papillomavirus vaccination of females in a large health claims database in the United States, 2006-2012. J Adolesc Health 2015; 56: 408-13.
57. Curtis CR, Dorell C, Yankey D, et al., National human papillomavirus vaccination coverage among adolescents aged 13-17 years-National Immunization Survey-teen, United States, 2011. MMWR Surveill Summ 2014; 63 (Suppl 2): 61-70.
58. Brotherton JM, Tabrizi SN, Garland SM., Does HPV type 16 or 18 prevalence in cervical intraepithelial neoplasia grade 3 lesions vary by age? An important issue for postvaccination surveillance. Future Microbiol 2012; 7: 193-99.
59. Baandrup L, Munk C, Andersen KK, et al., HPV16 is associated with younger age in women with cervical intraepithelial neoplasia grade 2 and 3. Gynecol Oncol 2012; 124: 281-85.
60. Howell-Jones R, Bailey A, Beddows S, et al., Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England. Br J Cancer 2010; 103: 209-16.
61. Joste NE, Ronnett BM, Hunt WC, et al., Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer. Cancer Epidemiol Biomarkers Prev 2015; 24: 230-40.
62. Australian Institute of Health and Welfare, Canberra. Cervical screening in Australia 2011 -2012. Available at: www.aihw.gov.au/publication-detail/?id=60129546865, accessed on August 28, 2015.
63. Saslow D, Castle PE, Cox JT, et al., American Cancer Society Guideline for Human Papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007; 57: 7-28.
64. Creighton P, Lew JB, Clements M, et al., Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years. BMC Public Health 2010; 10: 734
65. Cuzick J, Bergeron C, von Knebel Doeberitz M, et al., New technologies and procedures for cervical cancer screening. Vaccine 2012; 30 (Suppl 5): F107-116.
66. Chesson HW, Ekwueme DU, Saraiya M, et al., Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. Vaccine 2012; 30: 6016-19.
67. WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. ISBN 978 92 4 154869 4 (NLM classification: WP 480). (c) World Health Organization 2013.
68. Campos NG, Castle PE, Wright TC, et al., Cervical cancer screening in low-resource settings: A cost-effectiveness framework for valuing tradeoffs between test performance and program coverage. Int J Cancer 2015; 137: 2208-19.
69. Forman D, de Martel C, Lacey CJ, et al., Global burden of human papillomavirus and related diseases. Vaccine 2012; 30 (Suppl 5): F12-23.
70. Gillison ML, Alemany L, Snijders PJ, et al., Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine 2012; 30 (Suppl 5): F34-54.
71. Goldstone SE, Jessen H, Palefsky JM, et al., Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males. Vaccine 2013; 31: 3849-55.
72. Munoz N, Kjaer SK, Sigurdsson K, et al., Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010; 102: 325-39.
73. Gillison ML, Castellsague X, Chaturvedi A, et al., Eurogin Roadmap: comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix. Int J Cancer 2014; 134: 497-507.
74. Herrero R, Quint W, Hildesheim A, et al., Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS ONE 2013; 8: e68329
75. Lang Kuhs KA, Gonzalez P, Rodriguez AC, et al., Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial. J Infect Dis 2014; 210: 1890-1899.
76. De Martel C, Shiels MS, Franceschi S, et al., Cancers attributable to infections among adults with HIV in the United States. Aids 2015; 29: 2173-81.
77. Brisson M, Van de Velde N, Boily MC., Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics 2009; 12: 343-51.
78. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE., Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008; 14: 244-51.
79. Kim JJ, Goldie SJ., Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008; 359: 821-32.
80. Centers for Disease Control and Prevention (CDC). Human papillomavirus-associated cancers-United States, 2004-2008. MMWR 2012; 61: 258-61.
81. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, et al., Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 2013; 31: 4550-59.
82. Chaturvedi AK, Engels EA, Pfeiffer RM, et al., Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29: 4294-301.
83. Chaturvedi AK, Engels EA, Anderson WF, et al., Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008; 26: 612-19.
84. Schiffman M, Castle PE., The promise of global cervical-cancer prevention. N Engl J Med 2005; 353: 2101-104.
85. Kreimer AR, Pierce Campbell CM, Lin HY, et al., Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet 2013; 382: 877-87.
86. Fakhry C, Rosenthal BT, Clark DP, et al., Associations between oral HPV16 infection and cytopathology: evaluation of an oropharyngeal ''pap-test equivalent'' in high-risk populations. Cancer Prev Res (Phila) 2011; 4: 1378-84.
87. Kreimer AR, Johansson M, Waterboer T, et al., Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol 2013; 31: 2708-15.
88. de Martel C, Ferlay J, Franceschi S, et al., Global burden of cancers attributable to infections in 2008: A review and synthetic analysis. Lancet Oncol 2012; 13: 607-15.
89. Kreimer AR, Brennan P, Lang Kuhs KA, et al., Human papillomavirus antibodies and future risk of anogenital cancer: a nested case-control study in the European Prospective Investigation into Cancer and nutrition study. J Clin Oncol 2015; 33: 877-84.
90. Gillison ML, D'Souza G, Westra W, et al., Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100: 407-20.
91. Gillison ML, Chaturvedi AK, Anderson WF, et al., Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol 2015; 33: 3235-42.
92. Fakhry C, Westra WH, Li S, et al., Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008; 100: 261-69.
93. Fakhry C, Zhang Q, Nguyen-Tan PF, et al., Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol 2014; 32: 3365-73.
94. Guo T, Qualliotine JR, Ha PK, et al., Surgical salvage improves overall survival for patients with HPV-positive and HPV-negative recurrent locoregional and distant metastatic oropharyngeal cancer. Cancer 2015; 121: 1977-84.
95. Tristram A, Hurt CN, Madden T, et al., Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT VIN): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2014; 15: 1361-68.
96. Wang JW, Jagu S, Wu WH, et al., Seroepidemiology of human papillomavirus 16 (HPV16) L2 and generation of L2-specific human chimeric monoclonal antibodies. Clin Vaccine Immunol 2015; 22: 806-16.
97. Lyford-Pike S, Peng S, Young GD, et al., Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 2013; 73: 1733-41.
98. A Phase IB Multi-Cohort Study of MK-3475 in Patients with Advanced Solid Tumors. ASCO 50th Meeting, June 2014, Chicago, Il.
99. Lewis JS, Carpenter DH, Thorstad WL, et al., Extracapsular extension is a poor predictor of disease recurrence in surgically treated oropharyngeal squamous cell carcinoma. Mod Pathol 2011; 24: 1413-20.
100. Pfister DG, Spencer S, Brizel DM, et al., Head and neck cancers, Version 1.2015. J Natl Compr Canc Netw 2015; 13: 847-55; quiz 856.
101. Rettig EM, Wentz A, Posner MR, et al., Prognostic implication of persistent human papillomavirus type 16 DNA detection in oral rinses for human papillomavirus-related oropharyngeal carcinoma. JAMA Oncol 2015; 1: 907-15.
102. Dahlstrom KR, Anderson KS, Cheng JN, et al., HPV serum antibodies as predictors of survival and disease progression in patients with HPV-positive squamous cell carcinoma of the oropharynx. Clin Cancer Res 2015; 21: 2861-69.
103. Ahn SM, Chan JY, Zhang Z, et al., Saliva and plasma quantitative polymerase chain reaction-based detection and surveillance of human papillomavirus-related head and neck cancer. JAMA Otolaryngol Head Neck Surg 2014; 140: 846-54.
104. Fakhry C, Zhang Q, Nguyen-Tan PF, et al., Reply to B. O'Sullivan et al. J Clin Oncol 2015; 33: 1708-9.
105. O'Sullivan B, Adelstein DL, Huang SH, et al., First site of failure analysis incompletely addresses issues of late and unexpected metastases in p16-positive oropharyngeal cancer. J Clin Oncol 2015; 33: 1707-8.
106. Seme K, Maver PJ, Korac T, et al., Current status of human papillomavirus vaccination implementation in central and eastern Europe. Acta Dermatovenerol Alp Pannonica Adriat 2013; 22: 21-5.
107. Anttila A, Ronco G, Nicula F, et al., Organization of cytology-based and HPV-based cervical cancer screening. S2. In:, Anttila A, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S, Patnick J, Ronco G, Segnan N, Suonio E, Törnberg S, von Karsa L, eds. European guidelines for quality assurance in cervical cancer screening. Second edition, Supplements. Luxembourg: Office for Official Publications of the European Union, 2015. 69-108.
108. Brotherton JML., HPV prophylactic vaccines: lessons learned from 10 years experience. Future Virol 2015; 10: 999-1009.
109. Binagwaho A, Wagner CM, Gatera M, et al., Achieving high coverage in Rwanda's national human papillomavirus vaccination programme. Bull World Health Org 2012; 90: 623-8. doi: 10.2471/BLT.11.097253.
110. Dorji T, Tshomo U, Phuntsho S, et al., Introduction of a National HPV vaccination program into Bhutan. Vaccine 2015; 33: 3726-30.
111. Jit M, Brisson M, Portnoy A, et al., Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet Glob Health 2014; 2: e406-14.
112. Goldie SJ, O'Shea M, Campos NG, et al., Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 2008; 26: 4080-93.
113. van de Vooren K, Curto A, Garattini L., Curing cervical cancer or preventing it: a case of opportunity cost in the long run? Vaccine 2014; 32: 6867-69.
114. Gavi, The Vaccine Alliance. Available at: www.gavi.org, accessed on August 28, 2015.